An Open Label Multicenter Post Marketing Observational Study for the Evaluation of Quality of Life Outcomes and Tolerability of HUMIRA in Routine Clinical Use in Patients With RA PsA AS After Unsustainable Response to Disease Modifying Antirheumatic Drugs and or Biologicals.
Phase of Trial: Phase IV
Latest Information Update: 25 Jul 2011
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 07 Jun 2017 Biomarkers information updated
- 20 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jul 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.